- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI moves forward with Optison
Contrast agent developer Molecular Biosystems has completed phase II studies for its myocardial perfusion agent, Optison, and has submitted its results to the Food and Drug Administration. The trials consisted of six studies with 376 participants
Contrast agent developer Molecular Biosystems has completed phase II studies for its myocardial perfusion agent, Optison, and has submitted its results to the Food and Drug Administration. The trials consisted of six studies with 376 participants experiencing known or suspected coronary artery disease, and showed that Optison Myocardial Contrast Echocardiography (MCE) tests were comparable to the standard clinical tests, either SPECT or coronary angiography, according to San Diego-based MBI. MBI now plans to proceed to phase III clinical trials for the agent.
Meanwhile, sales of Optison continue outside the U.S. Optison was cleared for sale in Europe in 1998 (SCAN 5/27/98), and is sold there by MBIs marketing partner, St. Louis-based Mallinckrodt. Earlier this year, MBI signed a licensing agreement with Chugai Pharmaceuticals for marketing of the agent in Japan, South Korea, and Taiwan (SCAN 6/9/99).
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.
Can Innovations with AI Help Address the Impact of Staffing Shortages on Radiology Workflow?
October 7th 2024While staffing shortages in radiology continue to persist after the COVID-19 pandemic, current and emerging innovations powered by artificial intelligence (AI) may help facilities navigate these challenges and mitigate rising costs of health care.
